Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy.

Keidar M, Walk R, Shashurin A, Srinivasan P, Sandler A, Dasgupta S, Ravi R, Guerrero-Preston R, Trink B. · 2011

Read Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy. by Keidar M, Walk R, Shashurin A, Srinivasan P, Sandler A, Dasgupta S, Ravi R, Guerrero-Preston R, Trink B. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3241555.txt.

Introduction

Michael Keidar and colleagues reported that cold plasma can kill cancer cells selectively, in this 2011 paper in the British Journal of Cancer. Plasma is ionized gas, usually hot, but newer devices make it at near room temperature. Earlier laboratory and animal work hinted such plasma might attack tumors while sparing healthy tissue, and the team put that claim to direct tests.

In dishes, cold plasma eradicated cancer cells while leaving normal cells undamaged. In animals, it significantly shrank tumors. Measurements pointed to disturbed handling of reactive oxygen species and altered stress-response genes inside treated cancer cells. The authors argue that tumor ablation with cold plasma could transform cancer treatment. It would put another state of matter to medical use. They acknowledge, though, that the mechanisms of plasma-cell interaction remain debated.

Catalog record

CREATORKeidar M, Walk R, Shashurin A, Srinivasan P, Sandler A, Dasgupta S, Ravi R, Guerrero-Preston R, Trink B.
YEAR2011
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3241555

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy By M Keidar, R Walk, A Shashurin, P Srinivasan, A Sandler, S Dasgupta, R Ravi, R Guerrero-Preston, B Trink Published in: British Journal of Cancer DOI: 10.1038/bjc.2011.386 ABSTRACT Abstract Background: Plasma is an ionised gas that is typically generated in high-temperature laboratory conditions. However, recent progress in atmospheric plasmas has led to the creation of cold plasmas with ion temperature close to room temperature. Methods: Both in-vitro and in-vivo studies revealed that cold plasmas selectively kill cancer cells. Results: We show that: (a) cold plasma application selectively eradicates cancer cells in vitro without damaging normal cells; and (b) significantly reduces tumour size in vivo. It is shown that reactive oxygen species metabolism and oxidative stress responsive genes are deregulated. Conclusion: The development of cold plasma tumour ablation has the potential of shifting the current paradigm of cancer treatment and enabling the transformation of cancer treatment technologies by utilisation of another state of matter. Keywords: cold plasma, cancer treatment, tumour ablation Plasma is an ionised gas that is typically generated in high-temperature laboratory conditions. Recent progress in atmospheric plasmas has led to the creation of cold plasmas with ion temperature close to room temperature (Fridman, 2008; Fridman et al, 2008). Earlier studies demonstrated the non-aggressive nature of the cold plasma (Stoffels et al, 2002). After it was shown, albeit indirectly, that plasma can interact with organic materials without causing thermal/electric damage to the cell surface, several biological applications were examined (Stoffels et al, 2002, 2008). As evidence accumulates, it is becoming clear that low-temperature or cold plasmas have an increasing role to take part in biomedical applications. The potential use in biomedical applications has driven the development of a variety of reliable and user-friendly plasma sources (Laroussi and Lu, 2005; Becker et al, 2006; Stoffels et al, 2006; Fridman et al, 2008; Kong et al, 2009; Morfill et al, 2009). There is still some controversy with respect to the mechanism of plasma–cell interaction. Some authors are of the opinion that ion species have the most important role in plasma–cell interactions by triggering intracellular biochemistry (Fridman et al, 2009). Alternatively, others have suggested that neutral species have the primary role in some plasma–cell interaction pathways (Kalghatgi et al, 2009). Furthermore, the effects of various ion species may be highly selective; different species can have either ‘plasma-killing’ (such as O) or ‘plasma-healing’ (such as NO) effects (Fridman et al, 2008; Kong, 2009). The role of other species, such as O3 and OH, are not yet clear. Even less clear is the nature of the interaction between cold plasmas and cancer tissue. Only limited research into the utility of cold plasma for cancer therapy has been performed. For the most part, these in vitro studies are limited to skin cells and simple cellular responses to the cold plasma treatment (Kim et al, 2010; Zirnheld et al, 2010; Georgescu and Lupu, 2010). In addition, preliminary reports on plasma's in-vivo antitumour effect are reported (Vandamme et al, 2010). Recent studies have delineated the effects of cold plasma on both the cellular and sub-cellular levels. On the cellular level, plasma effects include detachment of cells from the extracellular matrix and decreased migration velocity of cells. On the sub-cellular level, cell surface integrin expression is reduced (Shashurin et al, 2008, 2010). In this study, we examined the therapeutic potential of a cold plasma jet in cancer cell lines and tumours, focusing on selective tumour cell eradication capabilities and signalling pathway deregulation. MATERIALS AND METHODS Cold plasma source The cold plasma source developed at GWU (Shashurin et al, 2008, 2010) is equipped with a pair of high-voltage (HV) electrodes, a central electrode and an outer ring electrode. Electrodes are connected to a secondary coil of HV resonant transformer operating at a voltage of about 2–5 kV and a frequency of about 30 kHz, with a helium flow rate of about 11 l min−1. The visible plasma jet had a length of approximately 5 cm and was well collimated along the entire length. According to previous studies (Shashurin et al, 2008, 2010), the plasma jet is discontinuous and represents a series of propagating plasma bullets. In-vitro assays Lung cancer cell lines We examined the normal human Bronchial epithelial (NHBE) and the lung cancer (SW900) cell lines. Cold plasma treatments were carried out at HV in the range of 3–5 kV, helium flow in the range 10–20 l min−1, distance from plasma source to cells of about 1 cm and treatment durations of about 30 s (Figure 3A). [Figure: (A) Cold plasma device; (B) typical image of mice with three tumours before and after treatment (shown after 24 h); (C and D) typical image of mice with a single tumour before and approximately 1 week after treatment; (E) tumour before and immediately after the 2.5-min treatment with cold plasma jet.] Murine melanoma cells B16-F10 melanoma cells were purchased from American Type Culture Collection (Manassas, VA, USA). Cells were cultured in D10 media (Dulbecco’s modified eagle’s medium (DMEM) containing 10% fetal calf serum, 1% penicillin/streptomycin and 1% L-glutamine). Primary macrophage harvest and growth Primary bone marrow macrophages were directly harvested from the tibias and femurs of killed mice. Cells were cultured in 30% L929 cell-conditioned media, re-fed on either day 2 or 3, and plated between days 6 and 9. Flow Cytometry Triplicate samples of 1 × 104 murine macrophages and B16-F10 melanoma cells were plated into 96-well plates with 100 μl of D10 media (DMEM (Sigma-Aldrich, St Louis, MO, USA)), supplemented with 10% fetal bovine serum, penicillin (100 IU ml−1), streptomycin (100 μg ml−1; Sigma-Aldrich) and 1% L-Glutamine (Mediatech Inc., Manassas, VA, USA)) per well. After cold plasma treatment, cells were collected and stained with fluorescein isothiocyanate-conjugated Annexin V and 7-aminoactinomycin D (7-AAD) obtained from BD Biosciences (San Jose, CA, USA). Flow cytometry was performed using FACS Calibur (BD Bioscience); results were analysed using FlowJo software (Ashland, OR, USA). In-vivo assays B16 and subcutaneous bladder cancer tumours (SCaBER) cells of 2 × 105 were subcutaneously injected into the right hind legs of 8 C57Bl6 mice (four control and four treated) and 10 nude mice (five control and five treated), respectively. B16 tumours were treated with cold plasma once they were approximately 5 mm in maximum diameter. Control mice received no therapy after inoculation. All treated mice received 5 min of cold plasma treatment. Tumours were treated through the skin; no overlying incisions were made. Mice received one round of treatment only. Tumour volumes were calculated using the formula V=0.52(X2Y). Control and treatment mice were killed when tumours reached a maximum diameter of 20 mm, if tumour bleeding or ulceration occurred, or if the mice appeared moribund. The cold plasma jet was also applied to nude mice bearing SCaBER. We examined the mouse skin after 2–5-min cold plasma treatment, to compare gross tissue damage to the skin before and after treatment. We extracted RNA to perform gene expression analyses. Gene expression assays A gene expression profile of treated and untreated tumour was obtained using the genome-wide HumanHT-12 v4 Expression BeadChip arrays (Illumina, San Diego, CA, USA). Each array on the HumanHT-12 Expression BeadChip targets more than 25 000 annotated

Read the complete text